Search

Author/Creator Levetan, Carly

1. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. (April 2018)

Authors:
Hiwase, Devendra; Tan, Peter; D'Rozario, James; Taper, John; Powell, Anthony; Irving, Ian; Wright, Matthew; Branford, Susan; Yeung, David T.; Anderson, Luke; Gervasio, Othon; Levetan, Carly; Roberts, Will; Solterbeck, Ann; Traficante, Robert; Hughes, Timothy
Journal:
Leukemia research
Issue:
Volume 67(2018)
Page Start:
109
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search